Illumina, Inc. (ILMN)
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84.
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
GRAL Stock Alert: 7 Things to Know as Grail Starts Trading Today
The world of biotech stocks got a new member today. Grail (NASDAQ: GRAL ) has successfully completed its spinoff from industry leader Illumina (NASDAQ: ILMN ).
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.
Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's decision to spin off its blood testing company – Grail.
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock.
Genetics sequencing leader Illumina reported a strong start to 2024. Nike has been lagging the S&P 500 this year.
Illumina to spin off Grail in June
Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail.
Illumina, Inc. (ILMN) Bernstein Strategic Decisions Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Bernstein Strategic Decisions Conference May 29, 2024 9:00 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Eve Burstein - Bernstein Research Eve Burstein Thanks so much for joining us. My name is Eve Burstein.
Principal Financial Group Inc. Has $26.40 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)
Principal Financial Group Inc. reduced its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 1.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 189,586 shares of the life sciences company’s stock after selling 2,774 shares during the period. Principal Financial Group Inc. owned 0.12% of Illumina worth $26,398,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds also recently made changes to their positions in ILMN. Park Avenue Securities LLC bought a new stake in Illumina during the 3rd quarter worth about $220,000. Panagora Asset Management Inc. raised its stake in shares of Illumina by 22.0% during the third quarter. Panagora Asset Management Inc. now owns 6,856 shares of the life sciences company’s stock worth $941,000 after buying an additional 1,236 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in Illumina by 2.6% in the third quarter. Teacher Retirement System of Texas now owns 12,250 shares of the life sciences company’s stock valued at $1,682,000 after buying an additional 305 shares during the period. Orion Portfolio Solutions LLC lifted its stake in shares of Illumina by 4.9% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,187 shares of the life sciences company’s stock valued at $3,870,000 after purchasing an additional 1,312 shares during the period. Finally, New Mexico Educational Retirement Board boosted its position in shares of Illumina by 7.8% in the 3rd quarter. New Mexico Educational Retirement Board now owns 8,250 shares of the life sciences company’s stock worth $1,133,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 89.42% of the company’s stock. Insider Transactions at Illumina In other news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.17% of the company’s stock. Illumina Stock Down 3.0 % Shares of ILMN stock opened at $111.07 on Monday. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market cap of $17.69 billion, a price-to-earnings ratio of -13.63 and a beta of 1.20. The firm’s 50-day moving average is $125.16 and its 200-day moving average is $127.00. Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 earnings per share. Sell-side analysts predict that Illumina, Inc. will post 0.87 EPS for the current year. Wall Street Analysts Forecast Growth Several research firms have weighed in on ILMN. Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Tuesday, May 7th. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, May 11th. Finally, OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $164.65. View Our Latest Report on ILMN About Illumina (Free Report) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
